Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile: an updated systematic review and meta-analysis
Standard
Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile: an updated systematic review and meta-analysis. / Mori, Keiichiro; Quhal, Fahad; Katayama, Satoshi; Mostafaei, Hadi; Laukhtina, Ekaterina; Schuettfort, Victor M; Sari Motlagh, Reza; Grossmann, Nico C; Rajwa, Pawel; Ploussard, Guillaume; Briganti, Alberto; Kimura, Takahiro; Egawa, Shin; Papalia, Rocco; Carrion, Diego M; Fiori, Cristian; Shariat, Shahrokh F; Esperto, Francesco; Pradere, Benjamin.
in: MINERVA UROL NEPHROL, Jahrgang 74, Nr. 3, 06.2022, S. 292-301.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile: an updated systematic review and meta-analysis
AU - Mori, Keiichiro
AU - Quhal, Fahad
AU - Katayama, Satoshi
AU - Mostafaei, Hadi
AU - Laukhtina, Ekaterina
AU - Schuettfort, Victor M
AU - Sari Motlagh, Reza
AU - Grossmann, Nico C
AU - Rajwa, Pawel
AU - Ploussard, Guillaume
AU - Briganti, Alberto
AU - Kimura, Takahiro
AU - Egawa, Shin
AU - Papalia, Rocco
AU - Carrion, Diego M
AU - Fiori, Cristian
AU - Shariat, Shahrokh F
AU - Esperto, Francesco
AU - Pradere, Benjamin
PY - 2022/6
Y1 - 2022/6
N2 - INTRODUCTION: The management of non-metastatic castration-resistant prostate cancer (nmCRPC) has undergone a paradigm shift with the development of androgen receptor axis-targeted (ARAT) agents. The updated results with final overall survival (OS) data of the phase III PROSPER, SPARTAN, and ARAMIS trials have recently been reported. Therefore, we performed an updated meta-analysis and network meta-analysis to indirectly compare the efficacy and safety of currently available treatments.EVIDENCE ACQUISITION: Multiple databases were searched for articles published before January 2021. Studies that compared OS and adverse events (AEs) in patients with nmCRPC were considered eligible.EVIDENCE SYNTHESIS: Three studies (n=4,117) met our eligibility criteria. Formal network meta-analyses were conducted. ARAT agent is associated with significantly longer OS compared to placebo (pooled hazard ratio (HR): 0.74, 95% confidence interval (CI): 0.65-0.83, P<0.001), with similar results shown for patients with both N1 and N0 disease (pooled HR 0.61 and pooled HR 0.76, respectively). In the network meta-analysis, apalutamide, darolutamide, and enzalutamide were more effective than placebo, with similar efficacies in terms of OS. For AEs (including any AEs, grade 3 or grade 4 AEs, grade 5 AEs, serious AEs, and AEs leading to treatment discontinuation), darolutamide was shown to be likely well tolerated. Quality-of-life was preserved in treatment arms irrespective of the drug.CONCLUSIONS: All three ARAT agents are efficacious options for the treatment of nmCRPC, whereas darolutamide appears to have the most favorable tolerability profile. These findings may facilitate individualized treatment strategies and inform future direct comparative trials.
AB - INTRODUCTION: The management of non-metastatic castration-resistant prostate cancer (nmCRPC) has undergone a paradigm shift with the development of androgen receptor axis-targeted (ARAT) agents. The updated results with final overall survival (OS) data of the phase III PROSPER, SPARTAN, and ARAMIS trials have recently been reported. Therefore, we performed an updated meta-analysis and network meta-analysis to indirectly compare the efficacy and safety of currently available treatments.EVIDENCE ACQUISITION: Multiple databases were searched for articles published before January 2021. Studies that compared OS and adverse events (AEs) in patients with nmCRPC were considered eligible.EVIDENCE SYNTHESIS: Three studies (n=4,117) met our eligibility criteria. Formal network meta-analyses were conducted. ARAT agent is associated with significantly longer OS compared to placebo (pooled hazard ratio (HR): 0.74, 95% confidence interval (CI): 0.65-0.83, P<0.001), with similar results shown for patients with both N1 and N0 disease (pooled HR 0.61 and pooled HR 0.76, respectively). In the network meta-analysis, apalutamide, darolutamide, and enzalutamide were more effective than placebo, with similar efficacies in terms of OS. For AEs (including any AEs, grade 3 or grade 4 AEs, grade 5 AEs, serious AEs, and AEs leading to treatment discontinuation), darolutamide was shown to be likely well tolerated. Quality-of-life was preserved in treatment arms irrespective of the drug.CONCLUSIONS: All three ARAT agents are efficacious options for the treatment of nmCRPC, whereas darolutamide appears to have the most favorable tolerability profile. These findings may facilitate individualized treatment strategies and inform future direct comparative trials.
KW - Androgen Receptor Antagonists/adverse effects
KW - Antineoplastic Agents/adverse effects
KW - Humans
KW - Male
KW - Prostatic Neoplasms, Castration-Resistant/drug therapy
KW - Quality of Life
U2 - 10.23736/S2724-6051.21.04431-1
DO - 10.23736/S2724-6051.21.04431-1
M3 - SCORING: Journal article
C2 - 34308608
VL - 74
SP - 292
EP - 301
JO - MINERVA UROL NEPHROL
JF - MINERVA UROL NEPHROL
SN - 2724-6051
IS - 3
ER -
